Moderna Shares Rise 13% Ahead of Third-Quarter Results Friday
Photo: TokenPost
Moderna shares climbed 13.1% to close at $258.38 on Nov. 4, a sharp move ahead of the biotechnology company’s scheduled third-quarter results on Friday. The stock’s Nov. 4 intraday high of $258.72 was 1.67% above its Oct. 21 intraday high of $254.48. On a closing basis, the Nov. 4 finish was 5.11% above the Oct. 21 close of $245.81. The WHO Technical Advisory Group on Candidate Vaccine Prioritization (TAG-CVP) recommended adding Moderna’s Ebola vaccine candidate mRNA-1469 to the ongoing Tumaini trial in the Democratic Republic of the Congo. The trial is a Phase 2/3 study.
Source: TokenPost
